永顺生物(839729) - 2022 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2022 was CNY 348,910,779.14, a decrease of 4.02% compared to the previous year[3] - The net profit attributable to shareholders was CNY 85,800,495.42, down 6.07% year-on-year[3] - Basic earnings per share decreased to CNY 0.31, reflecting a decline of 6.06% from the previous year[3] - The decline in revenue was primarily due to a decrease in technology transfer income by CNY 12,388,000[6] - The company experienced a significant recovery in performance in the second half of the year as pig prices rebounded[5] Assets and Equity - Total assets at the end of the reporting period were CNY 873,148,274.87, an increase of 7.91% compared to the beginning of the year[3] - Shareholders' equity attributable to the parent company was CNY 695,905,687.05, a decrease of 1.34% from the previous year[4] - The company’s net assets per share decreased to CNY 2.55, a decline of 1.16% from the previous year[4] Return on Investment - The weighted average return on net assets (excluding non-recurring items) was 12.35%, down from 13.32% in the previous year[3] Cautionary Note - Investors are advised to be cautious as the financial data presented is preliminary and unaudited, with potential discrepancies in the final annual report[7]